See more : Intelligent Oud Company for Trading (9579.SR) Income Statement Analysis – Financial Results
Complete financial analysis of InterCure Ltd. (INCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InterCure Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- AGNC Investment Corp. (0H6E.L) Income Statement Analysis – Financial Results
- New Generation Consumer Group, Inc. (NGCG) Income Statement Analysis – Financial Results
- Mitsuboshi Belting Ltd. (5192.T) Income Statement Analysis – Financial Results
- Komehyo Holdings Co.,Ltd. (2780.T) Income Statement Analysis – Financial Results
- Mauna Kea Technologies SA (MKEAF) Income Statement Analysis – Financial Results
InterCure Ltd. (INCR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.intercure.co
About InterCure Ltd.
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 355.55M | 388.68M | 219.68M | 65.04M | 8.93M | 0.00 | 0.00 | 0.00 | 1.40M | 5.65M | 8.25M | 8.47M | 12.07M | 13.23M |
| Cost of Revenue | 250.46M | 233.60M | 128.55M | 33.06M | 7.45M | 0.00 | 0.00 | 0.00 | 538.71K | 1.87M | 1.84M | 1.99M | 2.89M | 3.13M |
| Gross Profit | 105.10M | 155.08M | 91.13M | 31.98M | 1.48M | 0.00 | 0.00 | 0.00 | 862.71K | 3.78M | 6.41M | 6.47M | 9.18M | 10.10M |
| Gross Profit Ratio | 29.56% | 39.90% | 41.48% | 49.17% | 16.57% | 0.00% | 0.00% | 0.00% | 61.56% | 66.85% | 77.67% | 76.44% | 76.03% | 76.34% |
| Research & Development | 388.00K | 632.00K | 1.24M | 1.58M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 50.62K | 104.48K | 351.18K | 844.93K | 1.03M |
| General & Administrative | 64.30M | 91.72M | 30.73M | 17.86M | 76.36M | 9.81M | 1.12M | 1.40M | 2.02M | 3.17M | 2.88M | 4.52M | 5.16M | 8.59M |
| Selling & Marketing | 21.94M | 5.60M | 23.21M | 8.44M | 2.69M | 0.00 | 0.00 | 0.00 | 167.86K | 2.54M | 5.22M | 3.62M | 4.46M | 4.97M |
| SG&A | 86.24M | 97.32M | 53.94M | 26.30M | 79.05M | 9.81M | 1.12M | 1.40M | 2.19M | 5.71M | 8.10M | 8.14M | 9.63M | 13.56M |
| Other Expenses | 60.04M | 4.20M | 2.93M | 745.00K | 853.00K | 0.00 | 24.33K | 369.27K | 89.78K | 140.18K | 142.78K | 156.91K | 510.00K | 510.91K |
| Operating Expenses | 146.66M | 102.15M | 58.11M | 28.62M | 81.62M | 9.81M | 1.12M | 1.40M | 2.39M | 5.90M | 8.34M | 8.65M | 10.98M | 15.10M |
| Cost & Expenses | 397.12M | 335.76M | 186.65M | 61.68M | 89.06M | 9.81M | 1.12M | 1.40M | 2.92M | 7.77M | 10.19M | 10.64M | 13.87M | 18.23M |
| Interest Income | 4.55M | 844.00K | 130.00K | 21.00K | 141.00K | 0.00 | 0.00 | 0.00 | 19.52K | 0.00 | 0.00 | 3.74K | -68.51K | 3.55K |
| Interest Expense | 24.22M | 14.69M | 5.05M | 264.00K | 1.84M | 1.03M | 639.51K | 411.59K | 0.00 | 0.00 | 86.69K | 1.83M | 7.08M | 8.81M |
| Depreciation & Amortization | 13.17M | 11.70M | 7.39M | 3.25M | 23.00K | 10.00K | 4.00K | 979.00K | 870.52K | 23.36K | 142.78K | 112.08K | 224.55K | 496.72K |
| EBITDA | -23.90M | 64.50M | 37.45M | -34.53M | -21.20M | -10.12M | -1.09M | 0.00 | -1.64M | -3.77M | -1.88M | 45.38M | -1.65M | -4.60M |
| EBITDA Ratio | -6.72% | 16.59% | 17.11% | 2.78% | -237.55% | 0.00% | 0.00% | 0.00% | -116.99% | -39.08% | -22.79% | -25.10% | -13.65% | -34.76% |
| Operating Income | -41.57M | 52.80M | 28.19M | -1.45M | -80.14M | -10.62M | -3.98M | 1.20M | -2.51M | 2.67M | -1.94M | -2.17M | -1.80M | -5.00M |
| Operating Income Ratio | -11.69% | 13.58% | 12.83% | -2.23% | -897.78% | 0.00% | 0.00% | 0.00% | -179.11% | 47.28% | -23.47% | -25.67% | -14.95% | -37.82% |
| Total Other Income/Expenses | -19.72M | -6.79M | -9.45M | 92.00K | -3.15M | -2.18M | -1.28M | -938.57K | 627.79K | -1.12M | -4.67M | 45.62M | -4.96M | -7.51M |
| Income Before Tax | -61.29M | 43.84M | 18.74M | -38.31M | -3.67M | -12.80M | -5.26M | 265.42K | -1.88M | -3.79M | -6.61M | 43.44M | -6.76M | -12.52M |
| Income Before Tax Ratio | -17.24% | 11.28% | 8.53% | -58.90% | -41.10% | 0.00% | 0.00% | 0.00% | -133.98% | -67.13% | -80.08% | 512.92% | -56.01% | -94.64% |
| Income Tax Expense | 2.25M | 93.00K | 11.44M | -2.27M | -673.00K | -1.15M | 663.84K | 3.05M | -780.73K | 0.00 | 87.06K | 1.83M | 41.87K | 46.12K |
| Net Income | -61.96M | 44.82M | 7.30M | -36.04M | -3.00M | -12.80M | -5.26M | 265.42K | -1.88M | -3.79M | -6.61M | 43.44M | -6.80M | -12.56M |
| Net Income Ratio | -17.43% | 11.53% | 3.32% | -55.42% | -33.56% | 0.00% | 0.00% | 0.00% | -133.98% | -67.13% | -80.08% | 512.92% | -56.35% | -94.98% |
| EPS | -1.36 | 0.99 | 0.16 | -1.42 | -0.13 | -0.62 | -0.31 | 0.02 | -0.21 | -2.34 | -4.36 | 711.66 | -23.15 | -42.77 |
| EPS Diluted | -1.36 | 0.99 | 0.16 | -1.42 | -0.13 | -0.62 | -0.31 | 0.02 | -0.21 | -2.34 | -4.36 | 585.98 | -23.15 | -42.77 |
| Weighted Avg Shares Out | 45.56M | 45.35M | 46.92M | 25.40M | 23.30M | 20.60M | 16.78M | 12.58M | 8.85M | 1.62M | 1.51M | 380.97K | 293.74K | 293.74K |
| Weighted Avg Shares Out (Dil) | 45.57M | 45.35M | 46.92M | 25.40M | 23.30M | 20.60M | 17.11M | 12.90M | 8.85M | 1.62M | 1.51M | 462.21K | 293.74K | 293.74K |
Berner's Cookies Enters Europe Via Partnership With InterCure, Will Open Stores In Austria & U.K.
Cannabis brand Cookies announced Thursday its international expansion into Europe through a partnership with Israel-based marijuana company InterCure (NASDAQ:INCR). The parties signed a multi-year deal under which InterCure will establish Cookies stores and medical cannabis pharmacies in Austria and the...
It's Been a Blazing Hot Week for These 12 Cannabis Stocks
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
InterCure Ltd. (INCR) CEO Alex Rabinovitch on Q3 2021 Results - Earnings Call Transcript
InterCure Ltd. (INCR) CEO Alex Rabinovitch on Q3 2021 Results - Earnings Call Transcript
Israeli Cannabis Co. InterCure's Shares Up On Preliminary Q3 Record Revenue Of $19.41M
InterCure Ltd. (NASDAQ: INCR) (TSX:INCR) (TASE: INCR), doing business as Canndoc, r eported Monday preliminary unaudited revenue of CA$24 million ($19.41 million) for the third quarter of 2021.
InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market
NEW YORK, TORONTO and HERZLIYA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a...
InterCure: Internationally Profitable Cannabis (Podcast Transcript)
InterCure is the most profitable cannabis company outside North America and recently uplisted to Nasdaq. Israel's former Prime Minister, Chairman Ehud Barak and CEO Alex Rabinovitch join the podcast to discuss Israel's cannabis landscape and what investors can expect going...
InterCure: Internationally Profitable Cannabis (Podcast)
InterCure: Internationally Profitable Cannabis (Podcast)
InterCure: Ignored Uplisting
InterCure reported exceptional Q2'21 revenues with numbers up 400% over last year. The Israeli cannabis company recently uplisted to the Nasdaq to limited fanfare.
InterCure to Webcast Live at VirtualInvestorConferences.com September 9th
NEW YORK and TORONTO and HERZLIYA, Israel, Sept. 8, 2021 /PRNewswire/ -- InterCure Ltd.
InterCure Re-Announces its Record-Breaking Second Quarter Financial Results With 4 Times YOY Revenue Growth - Following NASDAQ Listing
Achieved record revenue of NIS 45 million (over CAD$17 million), an increase of 400% year-over-year and 37% quarter-over-quarter
Source: https://incomestatements.info
Category: Stock Reports